The Genomic Seminar Series is a forum for leading researchers to present their high-level vision for genetics, genomics and omics broadly, with a goal of appealing to scientists, clinicians and trainees across the Duke School of Medicine.
This seminar series will occur quarterly with some events occurring virtually only and others in-person with streaming options.
Each daily 1 hour lecture(s) is designated for 1 AMA PRA Category 1 Credit(s)™
CREDIT STATEMENT: Duke University Health System Department of Clinical Education and Professional Development designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity. In support of improving patient In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.
JA Accreditation Statement: In support of improving patient In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.
Monday, February 21, 2022
4:00 - 5:00 PM
103 Bryan Research; live stream will be available. Stay tuned for details
Register for in-person attendance
Director, National Human Genome Research Institute
Creating the Fourth Chapter of Human Genomics
The coming decade offers great promise for the field of human genomics. The growing insights gained from early studies of DNA and, in particular, the molecular biology revolution laid the foundation for the launch of the Human Genome Project just over three decades ago. Since then, genomics has become progressively entrenched within the bedrock of the biomedical research enterprise. Capitalizing on the momentum of the project’s successful completion in 2003, the field of genomics has since expanded and matured substantially, such that genomics now regularly plays a central and catalytic role in basic and translational research, and studies increasingly demonstrate the vital part that genomic information can play in clinical care. Looking ahead, the anticipated advances in technologies, biological insights, and clinical applications (among others) will lead to more widespread dissemination of genomics throughout biomedical research, a growing adoption of genomics into medical and public-health practices, and an increasing relevance of genomics in everyday life. To capitalize on these opportunities, the National Human Genome Research Institute is working to develop and implement new programs and initiatives that will help create the latest chapter in human genomics, with a particular emphasis on making genomics broadly and equitably integrated in medicine.
About Dr. Green
As NHGRI director, Dr. Green leads the Institute's research programs and other initiatives. Under his guidance, the Institute has completed two major cycles of strategic planning to ensure that its research investments in genomics effectively advance human health. These two strategic planning processes have guided a major expansion of NHGRI’s research portfolio, highlights of which include the design and launch of major new programs to accelerate the application of genomics to medical care, to catalyze the growth of genomic data science, to continue leading efforts to unravel the functional complexities of the human genome and to enhance the building of a robust and diverse genomics workforce of the future. Throughout his career, Dr. Green has authored and co-authored over 375 scientific publications.
Friday, April 22, 2022
12:00 - 1:00 PM
Zoom (link forthcoming)
Diana W. Bianchi, M.D.
Senior Investigator in the Center for Precision Health Research, National Human Genome Research Institute
Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development
Head of the Prenatal Genomics and Therapy Section, Medical Genetics Branch, NHGRI
Dr. Bianchi oversees research on pediatric health and development, maternal health, reproductive health, intellectual and developmental disabilities, and rehabilitation medicine, among other areas. Her translational research focuses on two broad themes: prenatal genomics with the goal of advancing noninvasive prenatal DNA screening and diagnosis and investigating the fetal transcriptome to develop new therapies for genetic disorders that can be given prenatally.
Dr. Bianchi's laboratory seeks to advance understanding of fetal and placental biology through sequence analysis of nucleic acids that circulate within the pregnant woman's blood. The information acquired is used to improve counseling and prenatal care. The laboratory has a long-term commitment to developing prenatal treatments for Down syndrome. They hypothesize that giving safe and efficacious medications to pregnant women who are carrying fetuses diagnosed with trisomy 21 will reduce oxidative stress and inflammation, promote the production of new fetal nerve cells, and lead to improvement in brain growth, all of which will ultimately improve brain function, learning and memory after birth.